Teladoc Health is doubling down on AI as it looks to reverse its financial slide. The telehealth giant announced two new capabilities within its Solo enterprise platform: SoloVitals, a contactless vital sign monitoring tool, and SoloScribe, an ambient AI documentation scribe. Both are designed to slot into workflows health systems already use — no extra hardware, no new vendor relationships.

SoloVitals uses remote photoplethysmography (rPPG) to detect subtle changes in facial skin color via existing camera-equipped devices, translating those signals into heart and respiratory rate measurements. SoloScribe, now generally available, records and transcribes clinical encounters — both in-person and virtual — and pushes structured notes directly into EHRs. A broad release of SoloVitals is expected in December.

The timing is deliberate. Teladoc posted a $200.3M net loss in 2025 and has since trimmed its 2026 revenue outlook, largely due to struggles at its BetterHelp mental health division. Expanding AI features within a single platform is a bid to attract health system clients fatigued by managing too many point solutions.

By the Numbers:

• $200.3M — Teladoc's net loss in 2025
• $2.36B–$2.45B — revised 2026 revenue guidance, down ~5% from earlier projections
• 15,000+ — care locations globally where the Solo platform is installed
• 2,000 — additional BetterHelp providers credentialed to accept insurance

Why it matters: As health systems push to do more with less, AI tools embedded in existing workflows could meaningfully reduce administrative burden and clinician burnout — while giving digital health companies like Teladoc a potential path back to growth.